Find and Pitch Jounalists, Get Your Story Covered

Tags: Software & Services Software Platforms IT Automation Apple cell biology, Craniofacial, developmental biology, DNA repair, genetics, oxidative stress

	Profile	Recent Articles on Subject
1	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	As financial headwinds pick up, pharmas are aiming to squeeze more ROI from their R&D - 27 days ago PharmaVoice’s Crystal Ball: The industry’s AI future - about 2 months ago 3 closely watched drugs that failed in the clinic - 3 months ago 2024 PharmaVoice 100s: Rare Disease Warriors - 4 months ago Is anyone taking the world’s priciest drugs? - 6 months ago Neuro drugs are still faltering, despite rising investment - 7 months ago Up-and-comers look for an edge in the bustling ADC field - 8 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 9 months ago After Vyvanse patent loss, Takeda’s neuroscience division looks to enter a new era - 10 months ago Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D - 12 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - about 1 year ago PharmaVoice 100s: Clinical trial gurus - over 1 year ago 3 recent FDA adcomm rejections — and why they matter - over 1 year ago
2	The Conversation Next Web The Heart of Tech ❤️ Amsterdam, The Netherlands technology	Will AI revolutionise drug development? Researchers say it depends on how it’s used - 27 days ago
3	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Oxford Drug Design achieves in vivo validation for novel cancer treatment - about 2 months ago
4	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Merck is broadening its pipeline as Keytruda’s patent cliff looms - about 2 months ago Oncology, obesity and more: Where pharma R&D is headed in 2025 - 3 months ago 3 FDA approval dates to watch in the year’s final push - 6 months ago Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors - 7 months ago To overcome barriers, cell and gene therapies need outside support - 7 months ago FDA’s platform designation aims to ease R&D pain points - 9 months ago Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies - 10 months ago As AI proliferates in pharma, regulators look to catch up in clinical trials - 10 months ago Black Diamond looks to outwit cancer mutations - 12 months ago For Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test - about 1 year ago
5	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Merck is a new year outlier with its diabetes drug - about 2 months ago
6	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Tuberculosis R&D funding is up, but still short of goals and dominated by a few players, report finds - 3 months ago STAT+: FDA agrees to review a rare disease drug that its developer was about to give up on - 11 months ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - about 1 year ago
7	<em>The Scientist</em> Staff The Scientist Exploring Life, Inspiring Innovation. scienceinnovation	New Frontiers in Vaccine Development - 3 months ago
8	Brittany Trang STAT News Health care business reporter. PhD. Indie rock fan. health carebusiness reporting	STAT+: Using AI to design small molecule drugs is tough. Here are five companies trying to crack the code - 3 months ago
9	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	Big Pharma earnings hang hope on the next generation of blockbusters - 4 months ago As new Alzheimer’s biomarkers come into play, here’s where the money is going - 5 months ago AlphaFold’s Nobel Prize is ‘the dawn of a new era’ in mapping drug development potential - 5 months ago Huntington’s disease R&D is regaining ground after several disappointments - 6 months ago Will the IRA squash new drugs? Those worries are likely exaggerated, studies say. - 6 months ago 23andMe inches closes to cancer immunotherapy, guided by its genetic database - 7 months ago A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients - 7 months ago The FDA pushes concrete plans to further diversity in clinical trials - 8 months ago After 33 years, Geron’s first approval marks a turn in Nobel-winning science - 8 months ago Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills’ - 9 months ago As Big Pharma places bigger bets on ADCs, here’s where the field is headed next - 9 months ago Now a biopharma powerhouse, Vertex’s R&D bedrock could deliver tomorrow’s blockbusters - 10 months ago With a rise in animal-human organ transplants, a drugmaker aims for a new standard of care - 11 months ago The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs - 12 months ago Big hopes for schizophrenia treatment rely on a deep pipeline of new approaches - 12 months ago The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround - about 1 year ago One biotech’s 3 gene therapy hurdles: delivery, delivery and delivery - about 1 year ago A biotech tackles drug discovery with transcription factor know-how - over 1 year ago
10	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: U.K. charities give $36 million to start new drugs for childhood tumors - 6 months ago

Journalists covering drug development